ClearNote Health
The NCI-led Vanguard study has selected tests from Guardant Health and ClearNote Health to move forward after a vigorous technology assessment.
U of Southampton to Use ClearNote Health Test in Large-Scale Pancreatic Cancer Surveillance Study
The epigenetic test will look for signs of pancreatic cancer among adults newly diagnosed with type 2 diabetes in a trial that aims to enroll up to 15,000 participants.
The company recently published data demonstrating its platform's potential use for prediction and monitoring of immunotherapy response for patients with lung cancer.
Personalis to Distribute ClearNote Health's Epigenomic Cancer Detection Tech
The company said that ClearNote's platform, which is being used to develop cancer early detection assays, would complement its own offerings.
The firm has commercialized its pancreatic cancer test and has its sights set on an ovarian cancer test launching in 2023.